Literature DB >> 19133710

Body mass index and weight gain as alternative or complementary hypothesis to explain olanzapine concentration-dose ratio accumulation.

Bruno Charpiat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19133710     DOI： 10.2165/0044011-200929020-00009

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  11 in total

Review 1.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Pharmacokinetics and tissue distribution of olanzapine in rats.

Authors:  M Aravagiri; Y Teper; S R Marder
Journal:  Biopharm Drug Dispos       Date:  1999-11       Impact factor: 1.627

Review 3.  Current options in the management of olanzapine-associated weight gain.

Authors:  E Kelly Hester; Margaret R Thrower
Journal:  Ann Pharmacother       Date:  2005-01-04       Impact factor: 3.154

4.  Weight gain during treatment of bipolar I patients with olanzapine.

Authors:  John Hennen; Roy H Perlis; Gary Sachs; Mauricio Tohen; Ross J Baldessarini
Journal:  J Clin Psychiatry       Date:  2004-12       Impact factor: 4.384

5.  Phenytoin and plasmapheresis: importance of sampling times and impact of obesity.

Authors:  K M Olsen; M A Marx; M S Monaghan; E Barnes; B H Ackerman; A A Pappas
Journal:  Ther Drug Monit       Date:  1994-12       Impact factor: 3.681

6.  Weight gain during long-term treatment with olanzapine: a case series.

Authors:  Egon Michael Haberfellner; Hans Rittmannsberger
Journal:  Int Clin Psychopharmacol       Date:  2004-07       Impact factor: 1.659

Review 7.  Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal.

Authors:  Mario Alvarez-Jiménez; César González-Blanch; Benedicto Crespo-Facorro; Sarah Hetrick; Jose Manuel Rodríguez-Sánchez; Rocio Pérez-Iglesias; Jose Luis Vázquez-Barquero
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Phenytoin disposition in obesity. Determination of loading dose.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Arch Neurol       Date:  1985-05

9.  Large intraindividual variability of olanzapine serum concentrations in adolescent patients.

Authors:  Christian J Bachmann; Michael Haberhausen; Monika Heinzel-Gutenbrunner; Helmut Remschmidt; Frank M Theisen
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

10.  Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.

Authors:  John K Darby; David J Pasta; Michael G Wilson; John Herbert
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.